Open AccessActivation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin αv‐mediated ADAM activity in hepatocellular carcinoma: A novel functional target for gefitinib
Author(s) -
Matsuo Mitsuhiro,
Sakurai Hiroaki,
Ueno Yoko,
Ohtani Osamu,
Saiki Ikuo
Publication year - 2006
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2006.00152.x
Subject(s) - hepatocellular carcinoma , pi3k/akt/mtor pathway , mapk/erk pathway , protein kinase b , cancer research , gefitinib , integrin , fibronectin , chemistry , signal transduction , medicine , microbiology and biotechnology , biology , cancer , epidermal growth factor receptor , biochemistry , receptor , extracellular matrix
We have shown that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) inhibits the development of intrahepatic metastases of hepatocellular carcinoma CBO140C12, and EGFR transactivation by tumor necrosis factor‐α is a possible target of gefitinib. In the present study, we focused on the fibronectin (FN)‐dependent signaling pathway to further elucidate the antimetastatic activity of gefitinib in CBO140C12 cells. We initially observed that FN induced activation of extracellular signal‐regulated kinase (ERK), p38 and Akt, as well as cell proliferation and CBO140C12 cell invasion. These responses were mediated by EGFR tyrosine kinase, because gefitinib inhibited these effects of FN. FN‐induced ERK, p38 and Akt activation was partly blocked by the Arg‐Gly‐Asp (RGD)‐pseudo‐peptide FC‐336, anti‐αv integrin antibody RMV‐7, the broad‐spectrum matrix metalloprotease inhibitor GM6001 and the broad spectrum a disintegrin and metalloprotease (ADAM) inhibitor TAPI‐1. But these inhibitors had no effect on EGF‐induced signaling pathways, suggesting that integrins and ADAM may be upstream components of EGFR in these responses. These results suggest that FN‐induced activation of ERK, p38, Akt, cell proliferation and invasion was mediated, at least in part, via integrins, ADAM and EGFR, and that this FN‐induced signaling pathway might be involved in the antimetastatic activity of gefitinib. ( Cancer Sci 2006; 97: 155 –162)